Canaccord analyst William Plovanic raised the firm’s price target on Pulmonx to $20 from $18 and keeps a Buy rating on the shares. The analyst said the pieces for additional growth remain, with the company’s reimbursement in Japan expected to be approved by year end as well as patient enrollment in the company’s IDE study for AeriSeal, which we believe can expand its TAM.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on LUNG:
- Pulmonx sees FY23 revenue $f $63M-$65M , consensus $62.1M
- Pulmonx reports Q4 EPS (38c), consensus (42c)
- Pulmonx Reports Fourth Quarter and Full Year 2022 Financial Results
- Pulmonx to Present at the Citi 2023 Healthcare Conference
- Pulmonx to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023
